Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Safety of Technosphere Insulin in Diabetes
NCT00308737Phase 3Completed
- Sponsor
- MannKind
- Start
- Jun 2005
- Primary completion
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by MannKind. Primary endpoints: Forced Expiratory Volume in 1 Second at 24 months and Forced Expiratory Volume in 1 Second Decrease at 24 months. Started Jun 2005; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00308737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308737.